A socially oriented non-financial development institution and a major organizer of international conventions, congress, exhibitions, business, social and sporting, public, and cultural events.

The Roscongress Foundation is a socially oriented non-financial development institution and a major organizer of international conventions; exhibitions; and business, public, sporting, and cultural events. It was established in pursuance of a decision by the President of the Russian Federation.

The Foundation was established in 2007 with the aim of facilitating the development of Russia’s economic potential, promoting its national interests, and strengthening the country’s image. One of the roles of the Foundation is to comprehensively evaluate, analyse, and cover issues on the Russian and global economic agendas. It also offers administrative services, provides promotional support for business projects and attracting investment, and helps foster social entrepreneurship and charitable initiatives.

Each year, the Foundation’s events draw participants from 208 countries and territories, with more than 15,000 media representatives working on-site at Roscongress’ various venues. The Foundation benefits from analytical and professional expertise provided by 5000 people working in Russia and abroad. In addition, it works in close cooperation with 163 economic partners; industrialists’ and entrepreneurs’ unions; and financial, trade, and business associations from 75 countries worldwide.

The Roscongress Foundation has Telegram channels in Russian (t.me/Roscongress), English (t.me/RoscongressDirect), and Spanish (t.me/RoscongressEsp). Official website and Information and Analytical System of the Roscongress Foundation: roscongress.org.

RC personal account
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона

Healthcare in Russia 2021

1 December 2021
Moscow, Russia

The Healthcare in Russia 2021 event will take place on 1 December 2021 at the Rossiya Segodnya International Multimedia Press Centre in Moscow. The organizers are the State Duma Committee of the Russian Federation on Health Protection and the Roscongress Foundation.

The event will play host to discussions on issues such as the spread of socially significant diseases, strategies to combat infectious threats and the importance of a values-based approach to dealing with the current economic challenges. A summary resolution will be drawn up to reflect the outcomes of each discussion track, and will form the basis of the programme for the Healthy Life Forum, which will take place at the upcoming Russian Investment Forum in 2022.

For queries about participating as a partner, please call:

Head of Division, Healthcare Directorate

+7 (812) 680 0034, ext. 1233
+7 (926) 388 2938


Business programme partners

Bristol-Myers Squibb

Bristol Myers Squibb is the company of breakthroughs — the kind that transform patients` lives. Dedicated to our mission of discovering, developing and delivering life-saving innovations that help patients prevail over serious diseases, we`ll never give up our search for more hope, for more people, around the world.

We focus on innovations, as we believe in the power of science to address some of the most challenging diseases of our time. We have a history of scientific excellence, transforming patient outcomes in major diseases such as cancer, cardiovascular disease, HIV and HCV. We pioneered a class of medicines that harnesses the power of the immune system to treat cancer.

Generating new ideas and thinking differently are at the heart of everything we do for patients. We are driven by the knowledge that our efforts can make the difference for a patient.

Alisa Dzhangiryants
Director of Market Access & Pricing Department, Bristol Myers Squibb

Boehringer Ingelheim

Boehringer Ingelheim concentrates on developing innovative therapies to improve the health and quality of life of humans and animals. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. The Company has the freedom to pursue its long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where it can do the most good.

Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Some 52,000 employees create value through innovation daily for the three business areas Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing. Investing in R&D the Company develops the breakthrough therapy to improve and extend patients’ lives.

Boehringer Ingelheim realizes more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, the Company accelerates the development of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

Read more: www.boehringer-ingelheim.ru.

Oliver Koehncke
General Director of Boehringer Ingelheim Russia

NPO Petrovax Pharm LLC

Petrovax is a Russian full-cycle biopharmaceutical company with 25 years of successful experience. It was founded in 1996 by a group of Russian scientists. Since 2014, the company has been a part of the Interros Group. The product portfolio includes original pharmaceutical products and vaccines, generics and dietary supplements. The company has its own research center and investment program for R&D, and holds more than 20 new molecule and manufacturing process patents. The company’s complex for manufacturing of APIs and finished dosage forms is located in the Moscow region and operates in full compliance with international GMP standards. Petrovax has over 800 employees.

Petrovax’s partners are the world’s leading pharmaceutical companies: Pfizer, Abbott, Boehringer Ingelheim. Petrovax is the largest Russian exporter of original medicinal products. The company exports products to the countries of the EAEU, the Middle East and the EU. In 2020-2021 Petrovax conducted large-scale trials of coronavirus vaccine and original medicines products against COVID-19 in Russia and the EU.

Mikhail Tsyferov
President, Member of the Board of Directors, NPO Petrovax Pharm LLC (part of the Interros Group)
Managing Director, Winter Capital Fund Private investor in several healthtech, edutech and fintech projects

Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity. For more information please visit: https://www.jnj.com/, https://jnj.ru/

Katerina Pogodina
Managing Director Russia & CIS, Janssen, pharmaceutical division of Johnson & Johnson, Director General Johnson & Johnson LLC


Philips ((NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2020 sales of EUR 19,5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


Novartis Group Russia

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.

Novartis products reach nearly 769 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 142 nationalities work at Novartis around the world. Find out more at www.novartis.ru or on Facebook, Instagram and YouTube social media NovartisRussia account pages.

Natalia Kolerova
Country President of Novartis Group Russia General Manager of the Novartis Oncology in Russia, Ukraine and CIS countries


GSK is a science-led global healthcare company with a special purpose — to help people do more, feel better, live longer. Being headquartered in the UK GSK operates in more than 150 countries and has 3 global businesses that discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Around 100 000 employees work for GSK around the world with more than 16,000 people working in R&D.

GSK has been operating in Russia since the 1980s and has now around 70 Rx products registered in the country. Our pharmaceutical business in Russia is presented in the following therapeutic areas: HIV, respiratory (asthma, COPD, allergic rhinitis), infectious diseases (antibacterial and antiviral medicines, vaccines), rheumatology and other.

GSK is among industry leaders in terms of investments in clinical trials in Russia.

Sean Reilly
VP & General Manager

«AstraZeneca Pharmaceuticals» LLC

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas — Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Irina Panarina
General Manager, AstraZeneca Russia and Eurasia